Prandase

Quick links to important sections

Prandase

Treatment option: Diabetes Mellitus

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prandase

What Type of Medicine is Prandase (Acarbose)?

Prandase is the trade name for the active ingredient Acarbose, which is an oral antidiabetic agent used by adults to improve glycemic control in the management of Type 2 Diabetes Mellitus. This medication belongs to a pharmacological class known as alpha-Glucosidase Inhibitors (AGIs). This classification reflects the drug's specialized function in regulating glucose derived from food. Unlike insulin secretagogues, Acarbose focuses its therapeutic action locally on carbohydrate digestion within the gastrointestinal tract, positioning it as a distinct option among antidiabetic therapies.

Acarbose: Composition, Form, and Origin

The core active ingredient, Acarbose, is chemically a complex pseudotetrasaccharide molecule. This substance is derived through a specialized microbial fermentation process, differentiating its origin from purely synthetic drugs. Prandase is supplied as tablets intended for oral administration and is a single-ingredient product. The oral dosage form is required because the drug must act precisely within the intestinal lumen.

General Purpose: How Prandase Contributes to Glycemic Control

The purpose of Prandase is to help adult patients maintain more stable blood sugar levels by acting as a starch blocker. This mechanism is specifically intended to mitigate postprandial hyperglycemia, which is the rise in blood glucose that follows a carbohydrate-rich meal. Acarbose is used to improve these post-meal glucose levels. By delaying the final enzymatic step of carbohydrate digestion, Prandase slows the absorption of glucose, supporting improved overall long-term glycemic control in individuals with Type 2 Diabetes Mellitus.

What side effects are possible with Prandase?

Possible Side Effects and Safety Information

This information describes the documented adverse reactions and safety restrictions for Prandase (acarbose), based on official government regulatory documents.


Frequency-Classified Adverse Reactions

The most frequent side effects are related to the gastrointestinal system and are often dose-dependent. These are classified according to regulatory frequency standards:

  • Very Common (Affecting more than 1 in 10 people): Flatulence, Diarrhea.
  • Common (Affecting up to 1 in 10 people): Abdominal pain.
  • Uncommon (Affecting up to 1 in 100 people): Nausea, Vomiting, Dyspepsia, and increases in liver enzyme values (transaminases).
  • Rare (Affecting up to 1 in 1,000 people): Jaundice, Hepatitis, Oedema (swelling), Rash, Urticaria.
  • Frequency Not Known: Intestinal obstruction (Subileus), Pneumatosis cystoides intestinalis, Thrombocytopenia, and severe allergic reactions (Hypersensitivity, Acute generalised exanthematous pustulosis).

Serious Safety Risks and Contraindications

Serious Adverse Reactions documented in regulatory sources include rare cases of severe hepatic injury (hepatitis or jaundice) and intestinal obstruction. Routine liver enzyme monitoring is recommended, particularly during the first year of treatment.

Risk of Hypoglycemia: When Prandase is used in combination with other anti-diabetic medications, such as insulin or sulfonylureas, the risk of low blood sugar (hypoglycemia) is present. If hypoglycemia occurs in this setting, it must be treated with glucose (dextrose), as the medicine delays the absorption of ordinary cane sugar.

Safety-Related Restrictions: Prandase is contraindicated (should not be used) in individuals with:

  • Severe kidney impairment (creatinine clearance < 25 ml/min).
  • Severe liver impairment.
  • Chronic intestinal diseases that involve marked digestion or absorption disorders (e.g., inflammatory bowel disease).
  • Conditions that may worsen from increased gas formation in the intestine (e.g., large hernias).

Overdose and Emergency Response

The official regulatory profile for a Prandase (Acarbose) overdose defines two distinct scenarios for potential risk and required action.

Documented Overdose Manifestations

When an overdose is taken alone, the documented clinical manifestation is a significant exacerbation of intestinal effects. These effects include severe diarrhea, flatulence, and tympanism (bloating/distension). This presentation is strictly contingent on the concurrent ingestion of carbohydrate-containing food. If the overdose occurs without food, these excessive intestinal effects are not expected to occur.

Required Emergency Action

The critical, life-threatening risk of overdose is severe hypoglycemia (critically low blood sugar), which is only a documented concern when Acarbose is combined with other antidiabetic agents, such as insulin or sulfonylureas. Regulators mandate that immediate medical attention must be sought if severe neurological symptoms of hypoglycemia—such as confusion, seizures, or loss of consciousness—develop.

Supportive Management

For supportive measures, the official labeling requires the immediate avoidance of all carbohydrate-containing food and drinks for 4 to 6 hours following the overdosage to limit intestinal effects. In the event of hypoglycemia, treatment must utilize glucose products, as common table sugar (sucrose) is explicitly stated as being unsuitable for rapidly counteracting the low blood sugar.

Therapeutic Uses of Prandase

Quick Facts

  • Primary Use: Supports the management of type 2 diabetes mellitus.
  • Benefit: May assist in improving glycemic control.
  • Role: Used as an addition to diet and physical activity.

Prandase (acarbose) is a therapeutic agent indicated for the management of type 2 diabetes mellitus. It is used in conjunction with adjustments to diet and physical activity to help improve blood sugar control. The medication is studied for its role in regulating post-meal (postprandial) glucose levels.

This agent may be used as a standalone treatment (monotherapy) or in combination with other prescribed antidiabetic medications, such as metformin, sulfonylureas, or insulin, to further support glycemic objectives. By working within the digestive tract, Prandase assists in delaying the absorption of carbohydrates, which contributes to a reduced increase in blood glucose following meals. This action is part of a comprehensive strategy to maintain overall blood sugar balance.

Eligibility and Restrictions for Use

Who Can and Cannot Use Prandase? — Official Regulatory Information

The eligibility for using Prandase (acarbose) is strictly defined by regulatory authorities and is determined by a patient’s age, reproductive status, and pre-existing medical conditions.

Eligibility Status by Population

Population Group Eligibility Status Regulatory Basis
Adults (18+ years) Eligible Indicated for Type 2 Diabetes Mellitus
Children/Adolescents (<18) Not Recommended Safety and efficacy not established
Pregnancy Not Recommended Insufficient data on safe use
Lactation (Breastfeeding) Not Recommended Unknown excretion into milk

Absolute Contraindications

Prandase is contraindicated and must not be used in specific patient populations, based on official labeling. These exclusions relate primarily to the drug’s action in the gastrointestinal tract and its metabolic effects:

  • Patients with known hypersensitivity to acarbose or its components.
  • Patients with Diabetic Ketoacidosis (DKA).
  • Patients with Inflammatory Bowel Disease (e.g., Crohn's disease, ulcerative colitis), colonic ulceration, or existing partial intestinal obstruction.
  • Patients with severe hepatic impairment, specifically cirrhosis.
  • Patients with severe renal impairment (typically defined as creatinine clearance less than 25 mL/min).

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory profile for Prandase (Acarbose) documents specific interaction patterns that primarily relate to its localized action within the gastrointestinal tract, affecting both glucose control and the systemic exposure of certain co-administered drugs. No specific drug-drug combinations are formally classified as contraindicated in official regulatory labeling.

Documented Interaction Patterns

Pharmacodynamic Interactions

Prandase may result in an additive glucose-lowering effect when co-administered with other antidiabetic agents, such as insulin or sulfonylureas.

Its therapeutic effect may be reduced by the concomitant use of intestinal adsorbents (e.g., charcoal) and digestive enzyme preparations that contain amylase or pancreatin. For this reason, these substances must not be taken concomitantly with Acarbose.

Exposure-Modifying Interactions

Prandase has been shown to alter the plasma levels of co-administered drugs. For instance, it reduces the mean peak plasma concentration and trough levels of digoxin. The peak plasma level of metformin may also be reduced, though the total amount absorbed is largely unchanged.

Concomitant administration with oral neomycin may enhance reductions in postprandial blood glucose and increase the frequency and severity of gastro-intestinal side effects. Simultaneous use of colestyramine should be avoided due to the enhanced effect of Acarbose.

Procedural and Population Constraints

The drug’s action dictates a crucial procedural constraint for managing acute low blood sugar (hypoglycemia): sucrose (table sugar) is unsuitable for rapid correction, and glucose (dextrose) must be used instead. A population-specific constraint exists in severe renal impairment (creatinine clearance less than 25 mL/min), where systemic exposure to Acarbose's active metabolite is significantly increased.

Mechanism of Action

Localized Inhibition of Intestinal alpha-Glucosidase

The core mechanism of Prandase is the specific, competitive, and reversible inhibition of the alpha-Glucosidase enzymes located exclusively on the brush border of the small intestine. By acting as a substrate mimic, the active ingredient, Acarbose, binds preferentially to enzymes like sucrase and maltase, physically blocking their ability to rapidly convert complex carbohydrates (starches, disaccharides) into simple, absorbable glucose molecules.

Modulating the Rate of Glucose Absorption Kinetics

This targeted inhibition modulates the rate of glucose entry into the bloodstream, which is a key pathway effect. The resulting molecular cascade prevents the sudden, massive influx of glucose that typically follows a carbohydrate-rich meal, forcing a slower, more prolonged process of absorption. This mechanism causes the attenuation of the magnitude and speed of the postprandial glucose surge, resulting in a more gradual systemic glucose kinetic profile.

Functional Constraints of the Peripheral Mechanism

The action is strictly peripheral and substrate-dependent, meaning it operates only within the digestive tract and only when complex carbohydrates are present. This defines the mechanism’s limitations; the drug is biologically inert and ineffective against already processed monosaccharides, such as pure glucose or dextrose, as they require no enzymatic breakdown for absorption.

Dosage and Administration Information

Official Route and Frequency

Prandase, containing the active ingredient Acarbose, is for oral administration. This medication is intended for continuous long-term treatment as part of a chronic management plan. The standard frequency is **three times daily.


Dosing Initiation and Adjustment

Dosing typically begins with a low starting quantity, often 25 mg or 50 mg three times per day, which allows for initial tolerance assessment. The dose is subject to gradual adjustment, or titration, made by the prescriber at intervals of 4 to 8 weeks, based on monitoring of postprandial glucose levels. The maximum daily dose is typically 300 mg, or 100 mg taken three times daily. A lower maximum of 50 mg three times daily applies to adult patients weighing 60 kg or less. Use is not recommended for individuals under 18 years of age.


Timing and Missed Doses

A critical condition for the proper use of Prandase is its timing relative to food. The tablet must be taken with the first bite of each main meal. If a dose is missed, the protocol is to skip the missed dose entirely and proceed to take the next scheduled dose at the beginning of the next meal. The tablets may be chewed with the first mouthful of food or swallowed whole with water immediately before the meal.

Recent Clinical Evidence

Research evidence / Overview of Studies for Prandase (Acarbose)


Evidence for Use in Type 2 Diabetes Management

Researchers utilized numerous Randomized Controlled Trials (RCTs) and systematic reviews to study acarbose in adults with Type 2 Diabetes Mellitus. These trials compared the agent as a standalone treatment (monotherapy) or as an addition to existing therapies. Research examined key blood sugar biomarkers as outcomes, including long-term measures like Glycosylated Hemoglobin ( HbA1c) and Postprandial Glucose (PPG) concentrations.

Studies reported measurements of changes in HbA1c and PPG concentrations within the observed time intervals. However, long-term effects beyond the study periods are not fully established. Many initial efficacy studies had follow-up durations that were limited to only a few months.


Evidence for Use in Delaying Type 2 Diabetes Onset

Acarbose was evaluated in studies involving individuals with Impaired Glucose Tolerance (IGT), often referred to as pre-diabetes. Large-scale, long-term, placebo-controlled trials were observed in this research scenario. The primary outcome studied was the incidence of new-onset Type 2 Diabetes Mellitus (T2DM) over several years of observation.

Findings indicated patterns related to the incidence of new T2DM diagnoses in the studied group compared to the control group. Data supporting this prevention indication is derived from a limited number of large-scale trials, and the results apply only to the populations studied. Research suggests that evidence quality varies across studies when applying findings to diverse populations.


Key Limitations and Areas of Research Uncertainty

Research highlights both what is known and what is still uncertain. One key limitation is the inconsistency of findings reported across systematic reviews regarding the agent’s association with major cardiovascular events in patients with established T2DM. Additionally, follow-up durations were limited in many of the core efficacy studies, meaning long-term effects on factors beyond blood sugar biomarkers are not fully established.

Frequently Asked Questions (FAQ)

Common questions about Prandase (FAQ)


Q: What is Prandase used for besides the main condition it treats?

Official documents indicate that while Prandase is approved for treating Type 2 Diabetes, it has also been the subject of research. Studies examined its potential to delay the onset of Type 2 Diabetes in individuals diagnosed with impaired glucose tolerance (prediabetes). This research suggests a secondary role in prevention, but its approved use remains centered on glycemic control.


Q: Does Prandase cure the condition or only manage the symptoms?

Prandase is classified as a long-term treatment intended to help manage a chronic condition. It works to improve overall glycemic control by slowing sugar absorption after meals. Regulatory information confirms the drug's purpose is management and control, not to cure the underlying disease.


Q: Is long-term use of Prandase considered safe according to official sources?

Official product information states that Prandase is intended for continuous long-term treatment. Common gastrointestinal side effects, such as gas and diarrhea, are frequently experienced at the beginning of treatment. Regulatory data indicates that these initial side effects often lessen over time with continued use of the medication.


Q: Are there any known withdrawal effects if Prandase is stopped suddenly?

Official studies indicate that stopping Prandase can result in objective changes in blood sugar markers. Specifically, long-term markers like HbA1c levels have been observed to increase and return toward pre-treatment concentrations after the medication is discontinued. This shows the drug's intended action ceases once administration stops.


Q: Does Prandase commonly cause weight gain or weight loss?

Regulatory sources confirm that the active ingredient in Prandase does not typically affect body weight. This sets it apart from some other diabetes medications which may be associated with weight change.


Q: Is feeling tired or drowsy a common side effect of Prandase?

Drowsiness or feeling tired is not typically classified as a common or very common side effect of Prandase when used alone. However, these symptoms are recognized signs of hypoglycemia (low blood sugar), which can occur if the medication is taken in combination with other anti-diabetic agents like insulin or sulfonylureas.


Q: How quickly do patients usually begin to feel the intended effects of Prandase?

The drug begins working immediately with the first bite of the meal to slow the absorption of starches and sugars. While this localized effect is instant, statistically significant improvements in long-term blood sugar markers, such as HbA1c, are typically observed after four to six months of continuous use.


Q: How does the body eliminate Prandase (how long does it stay in the system)?

The drug primarily acts locally within the intestine, meaning less than 2% of the active drug is actually absorbed into the bloodstream. The minimal amount that is absorbed is rapidly eliminated by the body. Once in the blood, the elimination half-life is approximately 2 hours.


Q: Can Prandase cause changes in mood or anxiety levels?

Changes in mood, nervousness, or anxiety are not generally classified as typical side effects of Prandase itself. Official information describes these symptoms as potential signs of hypoglycemia (low blood sugar). This risk is relevant when the medication is combined with certain other diabetes treatments.


Q: What side effects should prompt a user to contact their doctor?

The official product label highlights signs of severe complications for which seeking medical attention is important. These include symptoms of liver problems (such as jaundice or dark urine), severe or bloody diarrhea, severe constipation, or symptoms of potential intestinal obstruction.


Q: What should be done if someone accidentally takes more Prandase than prescribed?

Regulatory guidance suggests calling emergency services or a poison control center in the event of an accidental overdose. Product information notes that consumption of carbohydrates is typically advised against for the four to six hours following the overdose, as the drug's effect is only relevant when carbohydrates are present.


Q: Is it safe to drink alcohol while taking Prandase?

Regulatory warnings indicate that drinking alcohol while using Prandase may cause severe hypoglycemia (low blood sugar). Due to this potential risk, regulatory information states the use of alcohol should be discussed directly with a healthcare professional.


Q: Are there specific foods or beverages that should be avoided when taking Prandase?

While there are no specific foods prohibited by the regulatory label, adherence to a prescribed meal plan is typically emphasized. Official information indicates that consistently consuming a high-carbohydrate diet may worsen the gastrointestinal side effects of the medication, such as gas and diarrhea.


Q: Can a person take common over-the-counter pain relievers like acetaminophen or ibuprofen with Prandase?

Official safety information notes caution regarding the use of nonprescription medicines (such as common pain relievers like aspirin) while using Prandase. These should only be taken after discussion with a healthcare professional due to the potential for interactions that may need to be monitored.


Q: Does Prandase interact with common vitamins like Vitamin D or B12?

Due to the potential for interactions, patients are typically advised to inform a healthcare provider about all vitamins, minerals, and other nonprescription supplements being used. This allows the provider to check for any potential conflicts or need for monitoring.


Q: Is it safe to use herbal or dietary supplements while on Prandase?

Official safety guidance suggests informing a healthcare provider about all herbal products and other dietary supplements for assessment of potential interactions before they are used with Prandase.


Q: Is Prandase considered safe for elderly patients?

Regulatory research has specifically examined the use of the drug in a limited number of elderly individuals. Official reports indicate that Prandase has not been shown to cause different side effects or unique problems in older adults compared to younger adults.

How should Prandase be stored and disposed of?

How to Store and Dispose of Prandase (Acarbose)

Prandase tablets must be stored at room temperature, ensuring the storage location is protected from both excess heat and moisture. The medication should be kept in the container in which it was dispensed, and the container must remain tightly closed to maintain product stability. It is mandatory to keep Prandase out of the sight and reach of children.

Disposal Guidelines

Official disposal instructions require that unused or expired Prandase tablets are not flushed down the toilet. The proper method for discarding this medication is through a designated medicine take-back program or by following any specific disposal instructions provided by local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Prandase found in:

A-Z Index: